ConductScience.org, home

Comparison · NCT01674140-deaths

Everolimus vs Placebo: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Everolimus vs Placebo: deaths from any cause. Trial comparisons, record NCT01674140-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01674140-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1250.1050.148wilson
Risk in group 20.1330.1120.157wilson
Risk difference, group 1 minus group 2-0.00781-0.03890.0233newcombe hybrid score
Risk ratio, group 1 over group 20.9410.741.2log
Odds ratio, group 1 over group 20.9330.7071.23log
Number needed to treat, for one fewer death from any cause on Everolimus than on Placebo128from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1EverolimusPatients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.112896EG001
Group 2Placebo
Patients receive an approved endocrine therapy comprising tamoxifen citrate\*, goserelin acetate\*\* or leuprolide acetate\*\*, or aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo orally (PO) daily for 1 year in the absence of disease progression or unacceptable toxicity.~NOTE: \*Men receive tamoxifen citrate PO for 5 years. NOTE: \*\*Goserelin acetate or leuprolide acetate is given if patient is or becomes postmenopausal.
119896EG000

Harm

What it counts
Total, all-cause mortality
Time frame
Every 6 weeks while on protocol treatment. Once after protocol treatment, it is reported as late adverse events for every 6 months for first 2 years, then annually until 10 years from registration.

Source ClinicalTrials.gov

Trial

Title
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT number
NCT01674140
Phases
PHASE3
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Lead sponsor
SWOG Cancer Research Network
Results first posted
2023-12-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01674140-deaths